Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 1/2013

01-02-2013 | Original Article

Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases

Authors: A. Wiedemann, M. Kaeder, W. Greulich, H. Lax, J. Priebel, R. Kirschner-Hermanns, I. Füsgen

Published in: World Journal of Urology | Issue 1/2013

Login to get access

Abstract

Background

Urinary tract symptoms are an underestimated problem in multiple sclerosis (MS).

Objective

Hundred urodynamics of MS patients have been evaluated prospectively.

Design, setting and participants

In an inpatient rehabilitation, all persons with MS who also suffered from urinary tract symptoms received a voiding diary, post-void sonography and an urodynamic examination according to International Continence-Society-Standard.

Results and limitations

Between 10/2009 and 3/2011, 100 patients (79 women; 21 men; mean EDSS, 4.52 ± 2.26) were examined who had primary progressive MS (9×), relapsing–remitting MS (41×), secondary progressive MS (43×) and CIS (1×). The mean duration of MS was 10.26 ± 10.09 years and mean duration of LUTS, 6.9 ± 7.75 years. Urodynamic testing showed normal findings in 22 patients, detrusor overactivity in 7, increased bladder sensation without detrusor overactivity in 21, detrusor–sphincter dyssynergia in 26, detrusor hypocontractility in 12, detrusor acontractility in 4 and unclear diagnosis in 8 patients. Statistically significant risk factors for pathological urodynamic findings were as follows: wheelchair dependency, use of more than one incontinence pad per day and a MS type other than relapsing–remitting.

Conclusions

The urodynamic investigation at hand showed urinary tract dysfunction in 78 of 100 MS patients with lower urinary tract symptoms (LUTS). The long latency between the occurrence of MS and/or the beginning of LUTS and the first neuro-urological evaluation indicates a deficit in treatment. Beyond national guidelines, all MS patients should at regular intervals be questioned about LUTS and receive urodynamic assessment especially according to the presented risk profile.
Literature
1.
van der Mei IA, Simpson S Jr, Stankovich J, Taylor BV (2011) Individual and joint action of environmental factors and risk of MS. Neurol Clin 29(2):233–255PubMedCrossRef
2.
Wingerchuk DM (2011) Environmental factors in multiple sclerosis: epstein-barr virus, vitamin d, and cigarette smoking. Mt Sinai J Med 78(2):221–230PubMedCrossRef
3.
4.
Ramagopalan SV, Meier UC, Conacher M, Ebers GC, Giovannoni G, Crawford DH, McAulay KA (2011) Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis. Arch Neurol 68(4):469–472PubMedCrossRef
5.
Zhang Q, Lin CY, Dong Q, Wang J, Wang W (2011) Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun Rev 8:474–481
6.
Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah JK, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman M, Iivanainen M, Sevon M, Bhan V, Dilenge ME et al (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6(9):773–781PubMedCrossRef
7.
Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, Hagan R, Duggan M, Jordan S, McKenna M, Hutchinson M, Tubridy N (2011) Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 82(3):317–322PubMedCrossRef
8.
Orton SM, Ramagopalan SV, Para AE, Lincoln MR, Handunnetthi L, Chao MJ, Morahan J, Morrison KM, Sadovnick AD, Ebers GC (2011) Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci 305:116–120PubMedCrossRef
9.
Hawkes CH (2007) Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 13(5):610–615PubMedCrossRef
10.
Zamboni P, Galeotti R (2010) The chronic cerebrospinal venous insufficiency syndrome. Phlebology 25(6):269–279PubMedCrossRef
11.
Artemiadis AK, Anagnostouli MC, Alexopoulos EC (2011) Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 36(2):109–120PubMedCrossRef
12.
Greer JM, McCombe PA (2011) Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 234:7–18PubMedCrossRef
13.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef
14.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846PubMedCrossRef
15.
Khan F, Pallant JF, Shea TL, Whishaw M (2009) Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 31(19):1567–1576PubMedCrossRef
16.
Rantell A (2009) Lower urinary tract symptoms in women with multiple sclerosis: 2. Br J Nurs 18(15):16–18
17.
Pohar SL, Jones CA, Warren S, Turpin KV, Warren K (2007) Health status and health care utilization of multiple sclerosis in Canada. Can J Neurol Sci 34(2):167–174PubMed
18.
Koch T, Kralik D, Eastwood S, Schofield A (2001) Breaking the silence: women living with multiple sclerosis and urinary incontinence. Int J Nurs Pract 7(1):16–23PubMedCrossRef
19.
Luoto E, Jussilainen M, Sandell S (1993) Intermittent self-catheterization in multiple sclerosis. Sairaanhoitaja 1(1):17–20
20.
Lemack GE, Hawker K, Frohman E (2005) Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. Urology 65(5):854–857PubMedCrossRef
21.
Petersen T, Pedersen E (1984) Neurourodynamic evaluation of voiding dysfunction in multiple sclerosis. Acta Neurol Scand 69(6):402–411PubMedCrossRef
22.
Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Finazzi AE, Collura G, Vespasiani G (1999) Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 80(4):437–441PubMedCrossRef
23.
Welz-Barth A, Fusgen I, Melchior HJ (2000) 1999 rerun of the 1996 German Urinary Incontinence Survey: will doctors ever ask? World J Urol 18(6):436–438PubMedCrossRef
24.
Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, Van KP (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21(3):261–274PubMedCrossRef
25.
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452PubMedCrossRef
Metadata
Title
Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases
Authors
A. Wiedemann
M. Kaeder
W. Greulich
H. Lax
J. Priebel
R. Kirschner-Hermanns
I. Füsgen
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 1/2013
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-011-0820-y

Other articles of this Issue 1/2013

World Journal of Urology 1/2013 Go to the issue

Topic Paper

The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database

Original Article

Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols

Topic paper

Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes

Original Article

Technical difficulties of transumbilical laparoendoscopic single-site adrenalectomy: comparison with conventional laparoscopic adrenalectomy

Original Article

Autologous fibroblast transplantation at the vesico-ureteral junction as potential reconstructive cell replacement in an animal model

Topic paper

Urothelial carcinomas of the upper urinary tract are now recognised as a true and distinct entity from bladder cancer and belong fully to the broad spectrum of onco-urologic neoplasms